Kebirtecan

by Oncogene

Active ingredient: Irinotecan HCl trihydrate

Packs

About Irinotecan

Cytostatic

Uses

Second-line treatment of metastatic colorectal cancer that has failed to respond to an established 5-FU containing regimen.

How to take it

Adults: 350 mg/m² by IV infusion over 30-90 min every 3 wk. If patient develops severe neutropenia or severe diarrhoea reduce dose to 300 mg/m² and then 250 mg/m² in subsequent cycles. Continue treatment until disease progression or unacceptable toxicity. Children: Not recommended. IV: Administer by IV Infusion, usually over 90 min. D5W (500 mL) is the preferred diluent for most doses. Solutions diluted in NS may precipitate if refrigerated. Reconstitution: Dilute in D5W or NS to a final conc of 0.12-2.8 mg/mL. Due to the relatively acidic pH, irinotecan appears to be more stable in D5W than NS, D5W (500 mL) is the preferred diluent for most doses. Compatibility: Stable in D5W, NS.…

Side effects

Delayed diarrhoea, warn patient of risk and start high dose loperamide immediately. Neutropenia, monitor neutrophil count. Anaemia, thrombocytopenia. Liver impairment; perform liver function tests. Nausea, vomiting, acute cholinergic syndrome, asthaenia, alopecia, dyspnoea, cramps, paraesthesia. Infection, blood dyscrasias, GI upset, colitis, haemorrhoids, anorexia, wt loss, cholinergic syndrome, dizziness, dysgeusia, mucosal inflammation, pyrexia, fatigue, oedema, electrolyte disturbances, dehydration, hypotension, embolism, DVT, dysphonia, raised blood creatinine, blood alkaline phosphatase and INR, hypoalbuminaemia, acute renal failure, inf related reactions. Reports of interstitial…

Pregnancy and breastfeeding

Pregnancy: Positive evidence of risk: Use only when no safer alternative exists for a serious problem. Lactation: Contraindicated or not recommended. Contraindications: Chronic inflammatory bowel disease, bowel obstruction, hepatic impairment, renal impairment, severe myelosuppression. Precautions: Risk of severe neutropenia; instruct patient to report fever. Monitor FBCs weekly. Perform LFTs before initiating treatment and before each cycle. Asthma. Risk factors for respiratory or cardiac disorders. UGT1A1 deficiency. Previous Whipple procedure. BMI <18.5kg/m2. Asian ethnicity. Elderly. Previous abdominal or pelvic irradiation, irradiation concurrent with treatment. Risk of delayed…

Advice

This medication is administered by infusion. Report immediately if there is redness/swelling/pain/burning at infusion site or if you experience signs of dehydration (light headedness, fainting, dizziness) or severe diarrhoea. Contact prescriber if there is fatigue, fever, chills, unusual bruising or bleeding, unrelieved nausea, vomiting, changes in appetite, purulent vaginal discharge, chest pain, palpitations, difficulty in breathing, unhealed mouth sores. Take sufficient amount of fluids (2-3 litres per day) to maintain hydration, unless restricted by the prescriber. Avoid highly crowded places to prevent infection. Do not get vaccinated without consulting prescriber.

Full information on Irinotecan →

Interactions with Irinotecan

Neuromuscular blocking agents, carbamazepine, phenobarbital, phenytoin, rifampicin, azole antifungals, protease inhibitors, St John's wort, grapefruit juice, other CYP3A4 inducers or inhibitors, strong UGT1A1 inhibitors, anticoagulants, live vaccines, tacrolimus, ciclosporin, other hepatotoxic agents.

Tell your pharmacist or doctor about every medicine you take, including herbal products.

Need Kebirtecan? Ask us to source Kebirtecan and our pharmacist will call you back.

Other brands with the same ingredients

More from Oncogene

Compiled by Healify Pharmacy from published drug references. How we compile it →

Always consult a pharmacist or doctor.